Compare Quest Diagnostics Inc (DGX) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Msci Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Msci Inc trades at $565.48 (market cap $40.38B). The key difference: Msci Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Msci Inc for 82 Days on average.
| DGX | MSCI | |
|---|---|---|
Market Cap | $25.48B | $40.38B |
Volume | 941,866 | 414,140 |
Sector | Health | Financials |
52-Week High | $247.45 | $643.83 |
52-Week Low | $173.49 | $511.84 |
Typical Hold Time | 56 Days | 82 Days |
Enterprise Value | $31.23B | $46.54B |
Dividend Yield | 1.49% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
MSCI trades at $565.12, up 1.75% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $3.13B, net income of $1.20B, and high margins. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 slightly missed. The company maintains strong cash flow and completed the acquisition of First Street in August 2026, enhancing its climate risk analytics offerings.
Outlook remains positive with a consensus price target of $701.71, implying significant upside. Key opportunities include recurring revenue growth and expansion in private markets. Risks include high valuation multiples, debt levels, and market sensitivity to financial services demand. Investors should weigh strong profitability against premium pricing and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
